132 related articles for article (PubMed ID: 7460485)
1. Debrisoquine hydroxylation capacity: problems of assessment in two populations.
Inaba T; Otton SV; Kalow W
Clin Pharmacol Ther; 1981 Feb; 29(2):218-23. PubMed ID: 7460485
[TBL] [Abstract][Full Text] [Related]
2. Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals.
Kalow W; Otton SV; Kadar D; Endrenyi L; Inaba T
Can J Physiol Pharmacol; 1980 Sep; 58(9):1142-4. PubMed ID: 7459706
[TBL] [Abstract][Full Text] [Related]
3. Interethnic dissociation between debrisoquine and desipramine hydroxylation.
Rudorfer MV; Lane EA; Potter WZ
J Clin Psychopharmacol; 1985 Apr; 5(2):89-92. PubMed ID: 3988975
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
[TBL] [Abstract][Full Text] [Related]
5. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
Meier PJ; Mueller HK; Dick B; Meyer UA
Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
[TBL] [Abstract][Full Text] [Related]
6. Lack of congruence of S-carboxymethyl-L-cysteine sulphoxidation and debrisoquine 4-hydroxylation in a Caucasian population.
Haley CS; Waring RH; Mitchell SC; Shah RR; Idle JR; Smith RL
Xenobiotica; 1985 May; 15(5):445-50. PubMed ID: 4036168
[TBL] [Abstract][Full Text] [Related]
7. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective 4-hydroxylation of debrisoquine in Nigerians.
Lennard MS; Tucker GT; Woods HF; Iyun AO; Eichelbaum M
Biochem Pharmacol; 1988 Jan; 37(1):97-8. PubMed ID: 3337737
[No Abstract] [Full Text] [Related]
9. Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley and DA rats: comparison with in-vivo results.
Vincent-Viry M; Deshayes S; Mothe O; Siest G; Galteau MM
J Pharm Pharmacol; 1988 Oct; 40(10):695-700. PubMed ID: 2907535
[TBL] [Abstract][Full Text] [Related]
10. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
[TBL] [Abstract][Full Text] [Related]
11. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.
Philip PA; James CA; Rogers HJ
Eur J Clin Pharmacol; 1989; 36(3):319-21. PubMed ID: 2744073
[TBL] [Abstract][Full Text] [Related]
12. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Alván G; Grind M; Graffner C; Sjöqvist F
Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
[TBL] [Abstract][Full Text] [Related]
13. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
14. Polymorphic 4-hydroxylation of debrisoquine in chronic discoid psoriasis.
Chapman PH; Rawlins MD; Shuster S; Idle JR; Ritchie JC; Smith RL
Eur J Clin Pharmacol; 1981; 21(3):257-8. PubMed ID: 6895622
[No Abstract] [Full Text] [Related]
15. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
Gut J; Catin T; Dayer P; Kronbach T; Zanger U; Meyer UA
J Biol Chem; 1986 Sep; 261(25):11734-43. PubMed ID: 3745165
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
Du YL; Lou YQ
Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
[TBL] [Abstract][Full Text] [Related]
17. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
[TBL] [Abstract][Full Text] [Related]
18. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.
Woolhouse NM; Andoh B; Mahgoub A; Sloan TP; Idle JR; Smith RL
Clin Pharmacol Ther; 1979 Nov; 26(5):584-91. PubMed ID: 498701
[TBL] [Abstract][Full Text] [Related]
19. Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations.
von Bahr C; Birgersson C; Morgan ET; Eriksson O; Göransson M; Spina E; Woodhouse K
Xenobiotica; 1986 May; 16(5):391-400. PubMed ID: 3739365
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
